Continuous exposure of lymphoma cells to venetoclax resulted in the selection of clones with missense mutations of BCL2 BH3 domain thereby abrogating venetoclax binding and conferring drug-resistant phenotype [120]. Here, BCL2 is linked to lymphoma.